LVIGI is developed by Erasmus Medical Center.

What development phase is LVIGI in?

LVIGI is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

LVIGI

Erasmus Medical Center · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	LVIGI
Also known as	Saline 0.9% 1.6 ml, Lidocain 1.0% 0.4 ml
Sponsor	Erasmus Medical Center
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LVIGI CI brief — competitive landscape report
LVIGI updates RSS · CI watch RSS
Erasmus Medical Center portfolio CI